Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selecting for Cetuximab Responders in Advanced Head and Neck SCC
NCT02177838Terminated
- Sponsor
- Rutgers University
- Start
- Mar 2015
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of KL-140 in head and neck squamous cell carcinoma (HNSCC), sponsored by Rutgers University. Primary endpoint: Locoregional Control in Cetuximab Responders at 2 years. Started Mar 2015; status: terminated.
02
Drugs
KL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02177838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02177838.